AVROBIO, Inc (AVRO) Prices 4.35M Share Common Offering at $23/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
After-Hours Stock Movers 02/12: (RDFN) (FBIO) (AMAT) Higher; (BE) (NTAP) (CSCO) Lower (more...)
February 12, 2020 6:02 PM ESTToday's After-Hours Movers
Bloom Energy (NYSE: BE) 19% LOWER; today announced that the Company expects to present its fourth quarter and full year results on or before March 16, 2020 and to file its Annual Report on Form 10-K for the year ended December 31, 2019 in compliance with the required filing deadline. The Company also announced it will restate certain prior period financial statements due to an accounting error related to its Managed Services Agreements (MSAs). MSAs are one of the Companys three customer financing options to acquire Bloom Energy servers
Akerna Corp. (Nasdaq:... More
AVROBIO, Inc (AVRO) Announces Proposed $100M Public Offering of Common Stock
February 12, 2020 4:04 PM ESTAVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.
The company expects to grant the underwriters a 30-day... More
Avrobio Inc. (AVRO) PT Raised to $40 at Morgan Stanley
February 12, 2020 9:24 AM ESTMorgan Stanley analyst David Lebowitz raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $40.00 (from $37.00) while maintaining a Overweight rating.... More
Avrobio Inc. (AVRO) PT Raised to $36 at Wedbush
February 11, 2020 11:52 AM ESTWedbush analyst David Nierengarten raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $36.00 (from $32.00) while maintaining a Outperform rating after the company updated their gene therapy program in Fabry disease (AVR-RD-01) and gave a first look at their program in cystinosis (AVR-RD-04).
... MoreAvrobio Inc. (AVRO) PT Raised to $35 at Mizuho Securities
February 11, 2020 6:37 AM ESTMizuho Securities analyst Difei Yang raised the price target on Avrobio Inc. (NASDAQ: AVRO) to $35.00 (from $28.00) while maintaining a Buy rating.... More
